These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 27355512)

  • 21. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity.
    Dolton MJ; McLachlan AJ
    Int J Antimicrob Agents; 2014 Sep; 44(3):183-93. PubMed ID: 25106074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
    Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients.
    Zhao YC; Lin XB; Zhang BK; Xiao YW; Xu P; Wang F; Xiang DX; Xie XB; Peng FH; Yan M
    Clin Transl Sci; 2021 Mar; 14(2):702-711. PubMed ID: 33202102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.
    Siopi M; Siafakas N; Vourli S; Zerva L; Meletiadis J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3973-83. PubMed ID: 25896699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
    Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
    Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers.
    Cojutti P; Candoni A; Forghieri F; Isola M; Zannier ME; Bigliardi S; Luppi M; Fanin R; Pea F
    Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):474-9. PubMed ID: 26572687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019.
    Jenks JD; Seidel D; Cornely OA; Chen S; van Hal S; Kauffman C; Miceli MH; Heinemann M; Christner M; Jover Sáenz A; Burchardt A; Kemmerling B; Herbrecht R; Steinmann J; Shoham S; Gräber S; Pagano L; Deeren D; Aslam S; Taplitz R; Revankar SG; Baddley J; Mehta SR; Reed S; Slavin MA; Hoenigl M
    Clin Microbiol Infect; 2020 Jun; 26(6):784.e1-784.e5. PubMed ID: 31972317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.
    Martin JM; Macias-Parra M; Mudry P; Conte U; Yan JL; Liu P; Capparella MR; Aram JA
    Pediatr Infect Dis J; 2017 Jan; 36(1):e1-e13. PubMed ID: 27636722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Changing Epidemiology of Invasive Fungal Infections.
    Enoch DA; Yang H; Aliyu SH; Micallef C
    Methods Mol Biol; 2017; 1508():17-65. PubMed ID: 27837497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol.
    Kunitomi A; Hasegawa Y; Hashimoto H; Saito AM; Iida H
    Nagoya J Med Sci; 2018 Nov; 80(4):591-595. PubMed ID: 30587873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
    Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
    Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients.
    Lempers VJ; Meuwese E; Mavinkurve-Groothuis AM; Henriet S; van der Sluis IM; Hanff LM; Warris A; Koch BCP; Brüggemann RJ
    Med Mycol; 2019 Nov; 57(8):937-943. PubMed ID: 30759261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying factors affecting the pharmacokinetics of voriconazole in patients with liver dysfunction: A population pharmacokinetic approach.
    Tang D; Song BL; Yan M; Zou JJ; Zhang M; Zhou HY; Wang F; Xiao YW; Xu P; Zhang BK; Chen XJ; Xiang DX; Linh Banh H
    Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):34-43. PubMed ID: 30715804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifungal stewardship considerations for adults and pediatrics.
    Hamdy RF; Zaoutis TE; Seo SK
    Virulence; 2017 Aug; 8(6):658-672. PubMed ID: 27588344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients.
    Allegra S; De Francia S; De Nicolò A; Cusato J; Avataneo V; Manca A; Antonucci M; D'Avolio A
    Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):405-412. PubMed ID: 31965553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.
    Hope WW; Walsh TJ; Goodwin J; Peloquin CA; Howard A; Kurtzberg J; Mendizabal A; Confer DL; Bulitta J; Baden LR; Neely MN; Wingard JR;
    J Antimicrob Chemother; 2016 Aug; 71(8):2234-40. PubMed ID: 27121401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in the epidemiological landscape of invasive mould infections and disease.
    Lass-Flörl C; Cuenca-Estrella M
    J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i5-i11. PubMed ID: 28355462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
    Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
    Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.
    Huurneman LJ; Neely M; Veringa A; Docobo Pérez F; Ramos-Martin V; Tissing WJ; Alffenaar JW; Hope W
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2336-42. PubMed ID: 26833158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
    Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
    J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.